A Randomized, Double-blind, Placebo-controlled Clinical Trial of the Chinese Medicine Di-Tan Decoction for the Treatment of Alzheimer’s disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12004548

Enrollment

Unknown

Registered

2012-11-21

Start date

2013-04-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s disease

Interventions

DTD treatment group:DTD

Placebo control group:placebo

Eligibility

Sex/Gender

Male

Age

55 Years to 90 Years

Inclusion criteria

Inclusion criteria: a. Meet NINCDS/ADARA criteria; b. Aged 55 to 90 years; c. Meet the diagnosis of PTOO; d. Stable treatment of the western medicine over the last 4 weeks; e. Presence of mild to moderate dementia (score of =10 on the Mini-Mental State Examination (MMSE) and< 3 on Clinical Dementia Rating Scale (CDR); f. Normal liver and renal function in blood test.

Exclusion criteria

Exclusion criteria: a. AD accompanied with other dementia; b. AD accompanied with PD; c. Cannot persist with treatments and does not cooperate with treatment procedures, d. Allergic physique and allergic to Chinese or western medical drugs; e. Severe diseases (i.e. cancer, severe cardiovascular, hepatic, or renal disease or impaired red cell production).

Design outcomes

Secondary

Measure	Time frame
Mini-Mental State Examination (MMSE);Clinical Dementia Rating Scale (CDR);Phlegm Turbidity Obstructing the Orifices (PTOO);	—

Primary

Measure	Time frame
cognitive subscale of Alzheimer’s Disease Assessment;disability assessment for dementia (DAD);	—

Contacts

Public ContactLi Min

School of Chinese Medicine, Hong Kong Baptist University

bucmad@hkbu.edu.hk67008538

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 17, 2026